Methods for Diagnosing and Treating Learning or Mental Disordrs with SERCA2 Protein and miRNAs that regulate SERCA2 Levels (SJ-10-0003 and SJ-12-0020)
- 詳細技術說明
- None
- *Abstract
-
In Journal of Neuroscience articles published in 2010 and 2012, Dr. Stanislav Zakharenko, M.D., Ph.D. and colleagues reported that elevated levels of the SERCA2 protein contribute to cognitive and psychiatric symptoms. Studies in a mouse model of 22q11 deletion syndrome, a condition characterized by cognitive decline and increased risk of schizophrenia, show SERCA2 inhibitors rescued neuronal abnormalities found in these mice. Further studies in these mice and other mutant mice that carry a deletion of the Dgcr8 gene show that specific microRNAs that inhibit SERCA2, miR-25 and miR-185, rescue these neuronal abnormalities.
Keywords: SERCA2, schizophrenia, bipolar disorder, obsessive-compulsive disorders, autism spectrum disorder, miRNA, miR-25, miR-185
Granted Patents or Published Applications: U.S. Application Publication No. 2012/0232121, published September 13, 2012
Related Scientific References: Earls LR, Bayazitov IT, Fricke RG, Berry RB, Illingworth E, Mittleman G, Zakharenko SS; Dysregulation of presynaptic calcium and synaptic plasticity in a mouse model of 22q11 deletion syndrome; J Neuroscience 2010 Nov24;30(47):15843-55.
Earls LR, Fricke RG, Yu J, Berry R, Baldwin LT, Zakharenko SS; Age-dependent microRNA control of synaptic plasticity in 22q11 deletion syndrome and schizophrenic; J Neuroscience 10 Octeber 2012, 32(41):14132-14144.
Licensing Opportunities: We are currently seeking licensing opportunities in all fields for the development of this technology.
- 國家/地區
- 美國
